DK0507625T3 - Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner - Google Patents

Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner

Info

Publication number
DK0507625T3
DK0507625T3 DK92302992.0T DK92302992T DK0507625T3 DK 0507625 T3 DK0507625 T3 DK 0507625T3 DK 92302992 T DK92302992 T DK 92302992T DK 0507625 T3 DK0507625 T3 DK 0507625T3
Authority
DK
Denmark
Prior art keywords
beta
alpha
preparation
ketolactones
unsaturated
Prior art date
Application number
DK92302992.0T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Tomio Oda
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of DK0507625T3 publication Critical patent/DK0507625T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK92302992.0T 1991-04-04 1992-04-03 Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner DK0507625T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (1)

Publication Number Publication Date
DK0507625T3 true DK0507625T3 (da) 1996-09-16

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92302992.0T DK0507625T3 (da) 1991-04-04 1992-04-03 Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner

Country Status (11)

Country Link
US (1) US5229529A (el)
EP (1) EP0507625B1 (el)
JP (1) JPH089608B2 (el)
KR (1) KR970003125B1 (el)
AT (1) ATE141921T1 (el)
CA (1) CA2064481C (el)
DE (1) DE69213067T2 (el)
DK (1) DK0507625T3 (el)
ES (1) ES2093776T3 (el)
GR (1) GR3020903T3 (el)
TW (1) TW197439B (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT643051E (pt) * 1992-09-30 2000-06-30 R Tech Ueno Ltd Processo de producao de cetonas alfa,beta-insaturadas
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US20040234472A1 (en) 2001-04-20 2004-11-25 Jackson John K. Micellar drug delivery systems for hydrophobic drugs
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク. 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
WO2007091697A2 (en) * 2006-02-07 2007-08-16 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
EP2380606B1 (en) 2006-06-30 2018-03-21 Cook Medical Technologies LLC Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
US9382272B2 (en) 2009-01-22 2016-07-05 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP3881868B1 (en) 2013-02-15 2023-09-27 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス, インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
JP6615769B2 (ja) 2014-02-19 2019-12-04 アルデア ファーマシューティカルズ インコーポレイテッド ミトコンドリアアルデヒドデヒドロゲナーゼ2(aldh2)に結合する多環式アミド
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
EP4019007A1 (en) 2016-06-01 2022-06-29 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN110267650A (zh) 2017-01-05 2019-09-20 杏国新药股份有限公司 胰脏癌治疗
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
JP2022520220A (ja) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
EP4073088A1 (en) 2019-12-12 2022-10-19 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
EP4097134A1 (en) 2020-01-29 2022-12-07 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
CA3182472A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN116133671A (zh) 2020-07-14 2023-05-16 辉瑞公司 重组牛痘病毒
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
US20240010747A1 (en) 2020-11-13 2024-01-11 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (el) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
DE3574470D1 (en) * 1985-09-18 1990-01-04 Upjohn Co Stereoselective reduktion.
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center (2−クロロ−3−オキソ−1−アルケニル)−ビシクロ〔3.3.0〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
EP0394263B1 (en) * 1987-09-04 1994-03-16 The Upjohn Company Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
JPH0592965A (ja) 1993-04-16
US5229529A (en) 1993-07-20
DE69213067D1 (de) 1996-10-02
CA2064481A1 (en) 1992-10-05
ATE141921T1 (de) 1996-09-15
EP0507625B1 (en) 1996-08-28
KR970003125B1 (ko) 1997-03-14
CA2064481C (en) 1996-12-24
TW197439B (el) 1993-01-01
GR3020903T3 (en) 1996-11-30
KR920019771A (ko) 1992-11-20
JPH089608B2 (ja) 1996-01-31
EP0507625A1 (en) 1992-10-07
DE69213067T2 (de) 1997-01-16
ES2093776T3 (es) 1997-01-01

Similar Documents

Publication Publication Date Title
DK0507625T3 (da) Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner
ATE194601T1 (de) Verfahren zur herstellung von pyrimidinverbindungen
ES2103751T3 (es) Procedimiento para la obtencion de oxetanonas.
MX17846A (es) Proceso para la preparacion de nuevos derivados de 9h purina.
US4916250B1 (el)
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
ES551337A0 (es) Metodo de preparar derivados de b-carbolin-3-oxadiazolilo
UA8015A1 (uk) Спосіб одержання заміщених семікарбазонів або їх солей
IL80391A (en) Process for the preparation of decabromodiphenyl ether with improved thermal stability
NO922321D0 (no) Bis(fluormetyl)eter, fremgangsmaate for fremstilling, samtfremgangsmaate for fremstilling av difluormetan av bis(fluormetyl)eter
ES2086065T3 (es) Preparacion de tetrahidropiridinas sustituidas.
ATE38986T1 (de) Verfahren zur herstellung 1,6-disubstituierter 2- aminobenzimidazole.
ES2057289T3 (es) Procedimiento para la obtencion de octadienoles.
DK0643051T3 (da) Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
ES2077781T3 (es) Procedimiento para la fabricacion de difosfanos solubles al agua.
BG43004A3 (en) Method for preparing condensed as- triazines
ES513953A0 (es) "un procedimiento para la preparacion de 6-(3,6-dihidro-1(2h)-piridil)primidin-3-oxidos 2,4-disubstituidos".
BG43005A3 (en) Method for preparing condensed as- triazines
GB2097792B (en) 1,3-dihydro-2h-imidazol-2-ones
DK93884A (da) Fremgangsmaade til fremstilling af 1,5-dibeskyttede-1,5,10-triazadecaner, mellemprodukter derfor samt disses fremstilling
ATE9462T1 (de) Verfahren zur herstellung der 2-(2,4dichlorphenoxy)-phenylessigsaeure.
IT1254985B (it) Procedimento per la fabbricazione di un materiale refrattario ceramico contenente carbonio
JPS5488210A (en) 4-methyl-3-sulphenyl-3-penten-2-one and its preparation